Back to search results
NCT06713239

A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

Active, Not Recruiting
NAAges 18+InterventionalDiagnostic
Cleerly, Inc.
~1,000 participants
Updated 2026-06-05 on ClinicalTrials.gov
What's tested:Cleerly Labs and Cleerly ISCHEMIA

At a glance

Recruiting sites
0 of 21 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.
Measured over Through study completion- an average of 1 year
+3 more outcomes measured

Conditions

Coronary Artery Disease

Explore related trials

Coronary Artery Disease

Where it's being run

21 sites across 17 states
California4
Florida2
Alabama1
Colorado1
Illinois1
Iowa1
Kentucky1
Louisiana1

Study leadership

  • Todd Villines, MD · PRINCIPAL_INVESTIGATOR · University of Virginia
  • Maros Ferencik, MD · PRINCIPAL_INVESTIGATOR · Oregon Health and Science University

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

\> 18 years
Symptomatic patients with suspicion of CAD, including those referred for elective, non-urgent diagnostic testing (e.g. stress test)

Exclusion

LDL \< 100 mg/dL
Currently or previously treated beyond primary prevention guidelines
Suspected acute coronary syndrome or otherwise unstable clinical status
Planned cardiovascular procedure (e.g. coronary angiography, cardiac surgery, non-coronary vascular procedure)
Noninvasive or invasive CV testing for CAD within 1 year (e.g. invasive coronary angiography (ICA), coronary CT angiography (CCTA) including calcium scoring)
Known history of obstructive CAD (prior myocardial infarction, CABG or PCI, stenosis ≥50%)
Known EF ≤40% or other moderate to severe valvular or congenital cardiac disease
Contraindications to CCTA

What this trial measures

  • The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.Through study completion- an average of 1 year

    The primary endpoint is composed of multuple elements, which are to be compared between Coronary Plaque-Based care and the usual care arm, in a hierarchical fashion, using the win ratio approach: 1\. Improved diagnostic certainty of CAD

  • The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.Through study completion- an average of 1 year

    The primary endpoint is composed of multuple elements, which are to be compared between Coronary Plaque-Based care and the usual care arm, in a hierarchical fashion, using the win ratio approach: 2\. Reduction in LDL

  • The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.Through study completion- an average of 1 year

    The primary endpoint is composed of multuple elements, which are to be compared between Coronary Plaque-Based care and the usual care arm, in a hierarchical fashion, using the win ratio approach: 3\. Freedom from ICA without a finding of obstructive CAD

  • The primary objective of this study is to determine whether a management strategy improves efficiency and effectiveness.Through study completion- an average of 1 year

    The primary endpoint is composed of multuple elements, which are to be compared between Coronary Plaque-Based care and the usual care arm, in a hierarchical fashion, using the win ratio approach: 4\. Freedom from PCI without finding of clinically significant stenosis